Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: Summary results from the 24-week phase III RA-Beacon study

O. Zamani; B. Combe; H.-P. Tony; J. S. Burson; H. Tahir; Mikkel Østergaard; B. Augendre-Ferrante; A. Beselin; E. Larsson; M. Casillas; J. Smolen

doi:10.1093/rheumatology/kew144.005

Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: Summary results from the 24-week phase III RA-Beacon study

O. Zamani, B. Combe, H.-P. Tony, J. S. Burson, H. Tahir, Mikkel Østergaard, B. Augendre-Ferrante, A. Beselin, E. Larsson, M. Casillas, J. Smolen

Afdeling for Rygkirurgi, Led- og Bindevævssygdomme

Originalsprog	Engelsk
Artikelnummer	I93
Tidsskrift	Rheumatology (Oxford, England)
Vol/bind	55
Udgave nummer	Suppl. 1
ISSN	1462-0324
DOI	https://doi.org/10.1093/rheumatology/kew144.005
Status	Udgivet - 2016

Adgang til dokumentet

10.1093/rheumatology/kew144.005

Citationsformater

Zamani, O., Combe, B., Tony, H.-P., Burson, J. S., Tahir, H., Østergaard, M., Augendre-Ferrante, B., Beselin, A., Larsson, E., Casillas, M., & Smolen, J. (2016). Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: Summary results from the 24-week phase III RA-Beacon study. Rheumatology (Oxford, England), 55(Suppl. 1), Artikel I93. https://doi.org/10.1093/rheumatology/kew144.005

Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: Summary results from the 24-week phase III RA-Beacon study. / Zamani, O.; Combe, B.; Tony, H.-P. et al.
I: Rheumatology (Oxford, England), Bind 55, Nr. Suppl. 1, I93, 2016.

Publikation: Bidrag til tidsskrift › Konferenceabstrakt i tidsskrift › Forskning › peer review

Zamani, O, Combe, B, Tony, H-P, Burson, JS, Tahir, H, Østergaard, M, Augendre-Ferrante, B, Beselin, A, Larsson, E, Casillas, M & Smolen, J 2016, 'Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: Summary results from the 24-week phase III RA-Beacon study', Rheumatology (Oxford, England), bind 55, nr. Suppl. 1, I93. https://doi.org/10.1093/rheumatology/kew144.005

@article{97e937e17aad4e388729b8158848c1a5,

title = "Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: Summary results from the 24-week phase III RA-Beacon study",

author = "O. Zamani and B. Combe and H.-P. Tony and Burson, {J. S.} and H. Tahir and Mikkel {\O}stergaard and B. Augendre-Ferrante and A. Beselin and E. Larsson and M. Casillas and J. Smolen",

year = "2016",

doi = "10.1093/rheumatology/kew144.005",

language = "English",

volume = "55",

journal = "Rheumatology (Oxford, England)",

issn = "1462-0324",

publisher = "Oxford University Press",

number = "Suppl. 1",

}

TY - ABST

T1 - Efficacy and safety of baricitinib in patients with active rheumatoid arthritis and inadequate response to tumor necrosis factor inhibitors: Summary results from the 24-week phase III RA-Beacon study

AU - Zamani, O.

AU - Combe, B.

AU - Tony, H.-P.

AU - Burson, J. S.

AU - Tahir, H.

AU - Østergaard, Mikkel

AU - Augendre-Ferrante, B.

AU - Beselin, A.

AU - Larsson, E.

AU - Casillas, M.

AU - Smolen, J.

PY - 2016

Y1 - 2016

U2 - 10.1093/rheumatology/kew144.005

DO - 10.1093/rheumatology/kew144.005

M3 - Conference abstract in journal

SN - 1462-0324

VL - 55

JO - Rheumatology (Oxford, England)

JF - Rheumatology (Oxford, England)

IS - Suppl. 1

M1 - I93

ER -